Search clinical trials for: IBI939+ Sintilimab

Total 445 results

Fudan University

Not yet recruiting

cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria

Hepatocellular Carcinoma
Fudan University

Recruiting

TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
The First Affiliated Hospital of Soochow University
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

DLBCL

China
Fudan University

Recruiting

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

NSCLC Stage IV

China
The First Hospital of Jilin University

Active, not recruiting

Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer (Neo-Pre-IC)

IIIA Stage Non-small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Henan Cancer Hospital

Unknown

Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer

Small Cell Lung Cancer | Chemotherapy | Adoptive Cellular Immunotherapy | Maintenance | Extensive Disease

China
Fudan University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer

Gastric Cancer
Peking Union Medical College Hospital
Harbin Medical University; The First Affiliated Hospital of Xiamen University

Recruiting

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 3

China
Fudan University

Recruiting

TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Patients With Advanced Hepatocellular Carcinoma (TASK-02)

Hepatocellular Carcinoma

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Huashan Hospital

Recruiting

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer

Gastric Cancer

China
Sichuan Cancer Hospital and Research Institute
The First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaborators

Not yet recruiting

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital

Recruiting

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Gastric Cancer

China
Jun-Lin Yi, MD

Not yet recruiting

Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC) (LM-HNSCC)

Head and Neck Squamous Cell Carcinoma | Immunotherapy | Metastases | Stereotactic Body Radiotherapy

China
Sun Yat-sen University

Recruiting

Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL

Safety and Efficacy

China
Sun Yat-sen University

Not yet recruiting

Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

Angioimmunoblastic T-cell Lymphoma

China
Huiqiang Huang

Completed

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Safety and Efficacy

China
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
The First Hospital of Jilin University

Recruiting

Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma (MB07133)

Efficacy | Safety Issues | MTD

China
The First Hospital of Jilin University

Recruiting

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Lung Cancer

China
Zhejiang Cancer Hospital

Not yet recruiting

A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

Small Cell Lung Cancer Extensive Stage
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC (NeoPD1TNBC)

Triple Negative Breast Cancer

China
Fudan University

Completed

Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC

Esophageal Squamous Cell Carcinoma

China
Shanghai Chest Hospital

Recruiting

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Non-small Cell Lung Cancer | Minimal Residual Disease | Immunotherapy | Anti-angiogenesis

China
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable G/GEJ Cancer.

Gastric Cancer

China
Sun Yat-sen University

Recruiting

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Neoplasms

China
Sun Yat-sen University

Withdrawn

Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Metastatic Cancer | ICC

China
Sixth Affiliated Hospital, Sun Yat-sen University
Sun Yat-sen University

Recruiting

S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma

Chemotherapy Effect | Locally Advanced Gastroesophageal Junction Adenocarcinoma

China
Xin-Hua Xu

Recruiting

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

Oral Cavity Squamous Cell Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

China
Sun Yat-sen University
Fifth Affiliated Hospital, Sun Yat-Sen University; Ningbo Medical Center Lihuili...

Not yet recruiting

Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402) (HSBRT2402)

Hepatocellular Carcinoma

China
Wuhan Union Hospital, China

Recruiting

HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma

Recurrent Glioblastoma

China
Hospital de Mataró

Completed

Effect of Oral Menthol on the Swallow Response of Patients With Oropharyngeal Dysphagia Associated With Neurological Diseases and Aging

Deglutition Disorders
M.D. Anderson Cancer Center
S*BIO

Completed

Study of SB939 in Subjects With Myelofibrosis

Myeloproliferative Disorders

United States
Buhai Wang
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

Cervical Cancer | Uterine Cervical Neoplasms | Cervix Cancer | Cervical Neoplasms

China
Changhai Hospital

Recruiting

Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer

Rectal Cancer | Microsatellite Instability Low | Immunotherapy | Neoadjuvant Chemoradiation Therapy

China
Fudan University

Recruiting

The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma (IRIS)

High-Risk Localized Soft Tissue Sarcoma

China
The First Affiliated Hospital of Xiamen University

Recruiting

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Colorectal Neoplasms

China
Ruijin Hospital

Recruiting

Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer

Stage IIIC Gastric Cancer

China
Henan Cancer Hospital

Not yet recruiting

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Gastric Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Dizal Pharmaceuticals

Not yet recruiting

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) (JACKPOT33)

Non-Small-Cell Lung Cancer

China
Sichuan University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Stage IV NSCLC

China
The Second Hospital of Shandong University
Shandong Sunstem Biotechnology Co.,Ltd.

Unknown

Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment

Gastric Cancer

China
Wuhan Union Hospital, China
Huazhong University of Science and Technology

Recruiting

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis

Colorectal Cancer Metastatic | Liver Metastases

China
Zhejiang Cancer Hospital

Recruiting

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Jiangsu Simcere Biologics Co., Ltd

Recruiting

A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors

Advanced Solid Tumor | Cutaneous T Cell Lymphoma

China

Search clinical trials for: IBI939+ Sintilimab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations